Semaglutide (Wegovy®) is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial Body Mass Index (BMI) of ≥30 kg/m2 (obesity), or ≥27 kg/m2 to <30 kg/m2 (overweight) in the presence of at least one weight-related comorbidity e.g. dysglycaemia (prediabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||09/05/2022|
|Rapid review completed||09/06/2022|
|Rapid Review outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of semaglutide (Wegovy®) compared with the current standard of care, on the basis of the proposed price relative to currently available therapies.|